Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T6SU
|
||||
| Former ID |
DAP000574
|
||||
| Drug Name |
Phendimetrazine
|
||||
| Synonyms |
Adphen; Antapentan; Dyrexan; Fendimetrazina; Hyrex; Mephenmetrazine; Phendimetrazinum; Sedafamen; Wehless; Adipost (TN); Adphen (base); Appecon (TN); Bontril (TN); Bontril PDM (TN); Fendimetrazina [INN-Spanish]; Melfiat (TN); Obezine (TN); Phendiet (TN); Phendimetrazine (INN); Phendimetrazine [INN:BAN]; Phendimetrazinum [INN-Latin]; Plegine (TN); Statobex (TN); X-Trozine; Anorex-SR (TN); Prelu-2 (TN); Phendimetrazine, (2S-trans)-isomer; D-2-Phenyl-3,4-dimethylmorpholine; Morpholine, 3,4-dimethyl-2-phenyl; (+)-3,4-Dimethyl-2-phenylmorpholine; (+)-Phendimetrazine; (2R-trans)-3,4-Dimethyl-2-phenylmorpholine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenyltetrahydro-1,4-oxazine; 3-Phenyl-2-methylmorpholine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Exogenous obesity [ICD10:E66] | Approved | [551871] | ||
| Therapeutic Class |
Anorexigenic Agents
|
||||
| Company |
Sandoz Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H17NO
|
||||
| Canonical SMILES |
CC1C(OCCN1C)C2=CC=CC=C2
|
||||
| InChI |
1S/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3/t10-,12+/m0/s1
|
||||
| InChIKey |
MFOCDFTXLCYLKU-CMPLNLGQSA-N
|
||||
| CAS Number |
CAS 634-03-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-1B adrenergic receptor | Target Info | Antagonist | [536284] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Pathway Interaction Database | LPA receptor mediated events | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.